2024 ESC guidelines for the management of chronic coronary syndromes: developed by the task force for the management of chronic coronary syndromes of the …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular …
S Halvorsen, J Mehilli, S Cassese, TS Hall… - European heart …, 2022 - academic.oup.com
Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …
evidence shows that it can be considered medically appropriate to a given condition and if …
2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
1Department of Cardiology, Division of Electrophysiology, University Heart Center Zurich,
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
Switzerland; 2Age-Related Health Care, Tallaght University Hospital/Department of …
Bleeding avoidance strategies in percutaneous coronary intervention
For many years, bleeding has been perceived as an unavoidable consequence of strategies
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
aimed at reducing thrombotic complications in patients undergoing percutaneous coronary …
Validation of the academic research consortium high bleeding risk definition in contemporary PCI patients
Background Bleeding following percutaneous coronary intervention has important
prognostic implications. The Academic Research Consortium (ARC) recently proposed a list …
prognostic implications. The Academic Research Consortium (ARC) recently proposed a list …
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
Aims Patients at high bleeding risk (HBR) represent a prevalent subgroup among those
undergoing percutaneous coronary intervention (PCI). Early aspirin discontinuation after a …
undergoing percutaneous coronary intervention (PCI). Early aspirin discontinuation after a …
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
MA Occhiuzzi, G Lico, G Ioele, M De Luca… - European Journal of …, 2023 - Elsevier
The biochemical role of the PI3K/PKB/mTOR signalling pathway in cell-cycle regulation is
now well known. During the onset and development of different forms of cancer it becomes …
now well known. During the onset and development of different forms of cancer it becomes …
3-or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation
Objectives The aim of this study was to evaluate 2 abbreviated dual-antiplatelet therapy
(DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary …
(DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary …
Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective …
A growing number of patients undergoing percutaneous coronary intervention (PCI) with
stent implantation also have atrial fibrillation. This poses challenges for their optimal …
stent implantation also have atrial fibrillation. This poses challenges for their optimal …
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey
Since its introduction in 1977, percutaneous coronary intervention has become one of the
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …
most commonly performed therapeutic procedures worldwide. Such widespread diffusion …